- Home
- MRM vs NLSP Comparison
MRM vs NLSP Comparison
Compare MRM & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- NLSP
- Stock Information
- Founded
- MRM 2000
- NLSP 2015
- Country
- MRM Japan
- NLSP Switzerland
- Employees
- MRM N/A
- NLSP N/A
- Industry
- MRM Other Consumer Services
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- NLSP Health Care
- Exchange
- MRM Nasdaq
- NLSP Nasdaq
- Market Cap
- MRM 10.4M
- NLSP 12.4M
- IPO Year
- MRM 2020
- NLSP 2021
- Fundamental
- Price
- MRM $2.19
- NLSP $2.13
- Analyst Decision
- MRM
- NLSP
- Analyst Count
- MRM 0
- NLSP 0
- Target Price
- MRM N/A
- NLSP N/A
- AVG Volume (30 Days)
- MRM 6.6M
- NLSP 165.7K
- Earning Date
- MRM 05-20-2025
- NLSP 08-19-2025
- Dividend Yield
- MRM N/A
- NLSP N/A
- EPS Growth
- MRM 27.65
- NLSP N/A
- EPS
- MRM 0.18
- NLSP N/A
- Revenue
- MRM $52,786,758.00
- NLSP N/A
- Revenue This Year
- MRM N/A
- NLSP N/A
- Revenue Next Year
- MRM N/A
- NLSP N/A
- P/E Ratio
- MRM $14.33
- NLSP N/A
- Revenue Growth
- MRM 21.55
- NLSP N/A
- 52 Week Low
- MRM $0.34
- NLSP $1.30
- 52 Week High
- MRM $8.39
- NLSP $7.96
- Technical
- Relative Strength Index (RSI)
- MRM 64.42
- NLSP 51.99
- Support Level
- MRM $1.10
- NLSP $1.71
- Resistance Level
- MRM $3.53
- NLSP $2.18
- Average True Range (ATR)
- MRM 0.33
- NLSP 0.16
- MACD
- MRM 0.13
- NLSP 0.02
- Stochastic Oscillator
- MRM 44.81
- NLSP 82.19
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.